Bisantrene Preclinical Drug Study Published
Released
Released
Announcement PDF
ASX Announcement
MD Anderson Cancer Center Researchers Publish AML
Preclinical Study on Bisantrene Drug Combinations
§
Researchers from the MD Anderson Cancer Center in Texas have identified
Bisantrene drug combinations with superior efficacy in AML cells
§
This work showed synergy for Bisantrene when used in combination with
standard-of-care AML drugs
§
This research supports Race’s Phase II relapsed / refractory AML clinical trial
expected to begin at the Chaim Sheba Medical Center, Israel in Q2 CY2021
10 May 2021 – Race Oncology Limited (“Race”) is pleased to announce a team of
researchers, led by Professor Borje Andersson and Associate Professor Ben Valdez of
the MD Anderson Cancer Center (Texas, USA), have identified a number of clinically
translatable drug combinations that showed synergy with Bisantrene when tested in
Acute Myeloid Leukaemia (AML) cells.
This study1, sponsored by Race, has been published in the Journal of Clinical &
Experimental Oncology and is entitled “Synergism of the Anthracene-Derivative Anti-Cancer
Agent Bisantrene with Nucleoside Analogs and A Bcl-2 Inhibitor in Acute Myeloid Leukemia
Cells”.
The MD Anderson team identified that Bisantrene, when used in combination with the
standard-of-care AML drugs cytarabine, cladribine, fludarabine, clofarabine and/or
ABT199 (Ventoclax) showed enhanced activation of apoptosis (cell killing) in AML cells.
Combinations of three or more of these drugs with Bisantrene showed additional
synergism and effective cell killing at drug concentrations far below that observed when
the drugs were used on their own.
Race Chief Scientific Officer, Dr Daniel Tillett said: “This work provides the preclinical
data to support our upcoming Phase II relapsed / refractory AML trial at the Chaim Sheba
Medical Center, where patients will be treated with Bisantrene in combination with the
nucleoside analogs, clofarabine and fludarabine. This trial is scheduled to begin in Q2
CY2021. We are extremely excited about being able to quickly translate this work from the lab
into the clinic, where it has the potential to help AML patients in need.”
1. Valdez BC, Murray D, Li Y, Liu Y, Nieto Y, et al., (2021) Synergism of the Anthracene-Derivative Anti-Cancer Agent
Bisantrene with Nucleoside Analogs and A Bcl-2 Inhibitor in Acute Myeloid Leukemia Cells. J Clin Exp Oncol 10:4.
.
-ENDS-
Race Oncology Ltd ABN 61 149 318 749
Registered office: L36, 1 Macquarie Place, Sydney NSW 2000
www.raceoncology.com
About Race Oncology (ASX: RAC)
Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer
drug called Bisantrene.
Bisantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO)
protein. Overexpression of FTO has been shown to be the genetic driver of a diverse
range of cancers. Race is exploring the use of Bisantrene as a new therapy for
melanoma and clear cell renal cell carcinoma, which are both frequent FTO overexpressing cancers. The Company also has compelling clinical data for the use of
Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid
Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.
Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’
strategy for the clinical development of Bisantrene.
See more at www.raceoncology.com.
Release authorised by:
Media contact:
Phil Lynch, CEO/MD on behalf
Jane Lowe
of the Race Board of Directors
+61 411 117 774
phillip.lynch@raceoncology.com
jane.lowe@irdepartment.com.au
Race Oncology Ltd ABN 61 149 318 749
Registered office: L36, 1 Macquarie Place, Sydney NSW 2000
www.raceoncology.com
Share your feedback
Discover